Zigg- ref dapoxetine:
Mountain View, CA (October 26, 2005) – ALZA Corporation announced today that it has received a not approvable letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application for dapoxetine hydrochloride, an investigational compound for the treatment of premature ejaculation (PE).
ALZA Corporation is committed to developing safe and effective medicines that address important unmet medical needs. The company continues to believe that dapoxetine provides important benefits for men who suffer from PE. ALZA Corporation plans to address questions raised in the FDA letter and continue the global development program.
http://www.jnj. com/news/jnj_ne … 1026_164127.htm
Also look here:
Postatem obscuri lateris nescitis.